CSE Bulletin: Fundamental Change - Glenbriar Technologies Inc./Love Pharma Inc.

Le 29 septembreSeptember 2021) Love Pharma Inc., the issuer resulting from a Fundamental Change of Glenbriar Technologies Inc. (GTI.X), has been approved for listing.

Listing and disclosure documents will be available at www.thecse.com on the trading date.

Love Pharma Inc., is a specialized health and wellness company offering pharmaceutical and therapeutic products with proven technologies for which it has the exclusive rights to produce, package and sell thoughout Europe, North America and the United Kingdom. Many of the products are market-ready, with proven history of significant sales. The Company is focused on the global sexual wellness and enhancement market.

_________________________________

Love Pharma Inc., l'émetteur résultant d'un changement fondamental de Glenbriar Technologies Inc. (GTI.X), a été approuvé pour inscription.

Les documents de cotation et d'information seront disponibles sur www.thecse.com à la date de négociation.

Love Pharma Inc. est une société spécialisée dans la santé et le bien-être offrant des produits pharmaceutiques et thérapeutiques dotés de technologies éprouvées pour lesquelles elle détient les droits exclusifs de production, d'emballage et de vente en Europe, en Amérique du Nord et au Royaume-Uni. De nombreux produits sont prêts à être commercialisés, avec des antécédents avérés de ventes importantes. La Société se concentre sur le marché mondial du bien-être et de l'amélioration sexuelle.

Issuer/Émetteur: Love Pharma Inc.
Security Type/Titre:

Common Shares/Actions ordinaires

Symbol(s)/Symbole(s): LUV
Number of securities issued and outstanding/ Titres émis et en circulation: 314 919 945
Number of Securities reserved for issuance/ Titres réservés pour émission: 73 626 130
CSE Sector/Catégorie: Life Sciences/Sciences Biologiques
CUSIP : 547153 10 6
ISIN : CA 547153 10 6 4
Old/Vieux CUSIP& ISIN: 377904107/CA3779041076
Boardlot/Quotité: 1000
Consolidation: 1 New for 2 Old /1 nouveau pour 2 ancien
Trading Currency/Monnaie de négociation: CDN$/$CDN
Trading Date/Date de negociation: Le 30 septembre/September 2021
Other Exchanges/Autres marches: N/A
Fiscal Year end /Clôture de l'exercice financier: Le 30 septembre/September
Transfer Agent/Agent des transferts: Odyssey Trust Company

 

The Exchange is accepting Market Maker applications for LUV. Please email: Trading@theCSE.com

If you have any questions or require further information please contact Listings at (416) 367-7340 or E-mail: Listings@thecse.com

Pour toute question, pour obtenir de l'information supplémentaire veuillez communiquer avec le service des inscriptions au 416 367-7340 ou par courriel à l'adresse: Listings@thecse.com

News Provided by Newsfile via QuoteMedia

The Conversation (0)
Quantum Biopharma

Quantum BioPharma Announces Cash Reward of up to USD $7Million for Proof of Market Manipulation in its Stock

Reward to be Paid if Information Contributes Significant Evidence Leading to a Trial Victory or Settlement in Landmark USD $700 Million+ Lawsuit

Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) (FRA: 0K91) (“Quantum BioPharma” or the “Company”), a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions for the treatment of challenging neurodegenerative and metabolic disorders and alcohol... Keep Reading...
Imagion Biosystems

Phase 2 HER2 Clinical Trial Manufacturing Commenced, WSU Imaging Optimisation Program Underway

Imagion Biosystems (ASX: IBX) (Company or Imagion), a company dedicated to improving healthcare outcomes through the early detection of cancer utilising its proprietary MagSense® imaging technology, is pleased to provide shareholders with a progress update regarding the Company’s business and... Keep Reading...
Stethoscope on stacked gold coins, symbolizing healthcare costs or medical finance.

Trump Tariffs to Raise US Medical Device Costs, Hospitals Hold Off on Stockpiling

President Donald Trump’s new round of tariffs —this time targeting copper— has intensified concerns about rising costs across key sectors, including healthcare. But despite significant price pressures on steel, aluminum, and now copper, all vital to medical device production, there is no... Keep Reading...
Actinogen

Actinogen confirms 100th participant in XanaMIA phase 2b/3 Alzheimer’s disease trial and interim analysis timeline

Actinogen Medical ASX: ACW (“ACW” or “the Company”) is pleased to announce that the 100th participant in its pivotal XanaMIA phase 2b/3 randomized trial of Xanamem® for Alzheimer’s disease (AD) has now passed all screening tests and is scheduled for randomization and treatment in July. This... Keep Reading...
Emyria Limited

Medibank to Fund Emyria’s PTSD Program at Perth Clinic

Emyria Limited (ASX: EMD) (“Emyria”, or the “Company”) a leader in developing and delivering innovative mental health treatments, is pleased to announce that Medibank Private Limited (“Medibank”), Australia’s largest private health insurer, has commenced funding for eligible customers to access... Keep Reading...
ASX:HIQ

HITIQ Announces Exclusive Global Agreement with Shock Doctor for PROTEQT Instrumented Mouthguard

Common Shareholder Questions – Entitlement Offer

HITIQ Limited (ASX: HIQ) (HITIQ or the Company), a pioneer in concussion management, proudly announces an exclusive global agreement with Shock Doctor, the world’s leading mouthguard innovator. This landmark agreement marks Shock Doctor’s two-year effort to design a mouthguard that will... Keep Reading...

Latest Press Releases

Related News